Advertisement

Osteoporosis International

, Volume 29, Issue 3, pp 717–722 | Cite as

Hip fracture trends in the United States, 2002 to 2015

  • E. Michael Lewiecki
  • N. C. Wright
  • J. R. Curtis
  • E. Siris
  • R. F. Gagel
  • K. G. Saag
  • A. J. Singer
  • P. M. Steven
  • R. A. Adler
Original Article

Abstract

Summary

An analysis of United States (US) Medicare claims data from 2002 to 2015 for women aged ≥ 65 years found that age-adjusted hip fracture rates for 2013, 2014, and 2015 were higher than projected, resulting in an estimated increase of more than 11,000 hip fractures.

Introduction

Hip fractures are a major public health concern due to high morbidity, mortality, and healthcare expenses. Previous studies have reported a decrease in the annual incidence of hip fractures in the US beginning in 1995, coincident with the introduction of modern diagnostic tools and therapeutic agents for osteoporosis. In recent years, there has been less bone density testing and fewer prescriptions for osteoporosis treatments. The large osteoporosis treatment gap raises concern of possible adverse effects on hip fracture rates.

Methods

We assessed hip fracture incidence in the US to determine if the previous decline in hip fracture incidence continued. Using 2002 to 2015 Medicare Part A and Part B claims for women ≥ 65 years old, we calculated age-adjusted hip fracture rates, weighting to the 2014 population.

Results

We found that hip fracture rates declined each year from 2002 to 2012 and then plateaued at levels higher than projected for years 2013, 2014, and 2015.

Conclusions

The plateau in age-adjusted hip fracture incidence rate resulted in more than 11,000 additional estimated hip fractures over the time periods 2013, 2014, and 2015. We recommend further study to assess all factors contributing to this remarkable change in hip fracture rate and to develop strategies to reduce the osteoporosis treatment gap.

Keywords

DXA Fracture Medicare Osteoporosis Reimbursement 

Notes

Acknowledgements

Chris Hogan of Direct Research, LLC, participated in the development of this manuscript by extracting, collecting, and categorizing data from primary CMS dataset sources.

Funding

Acquisition and analysis of data for this study was provided by the National Bone Health Alliance and the International Society for Clinical Densitometry.

Compliance with ethical standards

Conflicts of interest

Dr. Lewiecki has received institutional grant/research support from Amgen, Merck, and Lilly; he has served on scientific advisory boards for Amgen, Merck, Lilly, and Radius. Dr. Steven is a paid data analyst for the International Society for Clinical Densitometry. Dr. Siris is a consultant for Amgen and Radius. Dr. Wright has received institutional grant/research support from Amgen and is a consultant for Pfizer. Dr. Saag has received research grants from Amgen, Lilly, and Merck and has served on scientific advisory boards for Amgen, Merck, and Radius. Dr. Adler has nothing to disclose. Dr. Singer has served on scientific advisory boards for Amgen, Lilly, and Radius; is a consultant for Amgen, Lilly, Merck, Radius, Medtronic, and Hologic; and is on the speakers’ bureau for Amgen and Lilly. Dr. Gagel has nothing to disclose.

References

  1. 1.
    US Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. US Department of Health and Human Services, Office of the Surgeon General, RockvilleGoogle Scholar
  2. 2.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475.  https://doi.org/10.1359/jbmr.061113 CrossRefPubMedGoogle Scholar
  3. 3.
    Gu Q, Koenig L, Mather RC 3rd, Tongue J (2014) Surgery for hip fracture yields societal benefits that exceed the direct medical costs. Clin Orthop Relat Res 472(11):3536–3546.  https://doi.org/10.1007/s11999-014-3820-6 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3–S7.  https://doi.org/10.1007/s00198-004-1702-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Dyer SM, Crotty M, Fairhall N, Magaziner J, Beaupre LA, Cameron ID, Sherrington C, Fragility Fracture Network Rehabilitation Research Special Interest G (2016) A critical review of the long-term disability outcomes following hip fracture. BMC Geriatr 16:158CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Riggs BL, Melton LJ III (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(Suppl):505S–511S.  https://doi.org/10.1016/8756-3282(95)00258-4 CrossRefPubMedGoogle Scholar
  7. 7.
    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302(14):1573–1579.  https://doi.org/10.1001/jama.2009.1462 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gillespie CW, Morin PE (2017) Trends and disparities in osteoporosis screening among women in the United States, 2008–2014. Am J Med 130(3):306–316.  https://doi.org/10.1016/j.amjmed.2016.10.018 CrossRefPubMedGoogle Scholar
  9. 9.
    Lewiecki EM, Adler RA, Curtis JR, Gagel R, Saag KG, Singer AJ, Siris E, Wright NC, Yun H, Steven PM (2016) Hip fractures and declining DXA testing: at a breaking point? J Bone Miner Res 31:S26Google Scholar
  10. 10.
    Centers for Medicare & Medicaid Services. Physician fee schedule search. U.S. Centers for Medicare & Medicaid ServicesGoogle Scholar
  11. 11.
    The Lewin Group (2007) Assessing the costs of performing DXA services in the office-based setting (survey data report prepared for American Association of Clinical Endocrinologists. International Society for Clinical Densitometry, The Endocrine Society, and American College of Rheumatology). The Lewin GroupGoogle Scholar
  12. 12.
    Lee E, Wutoh AK, Xue Z, Hillman JJ, Zuckerman IH (2006) Osteoporosis management in a Medicaid population after the Women’s Health Initiative study. J Women's Health (Larchmt) 15(2):155–161.  https://doi.org/10.1089/jwh.2006.15.155 CrossRefGoogle Scholar
  13. 13.
    Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res 30(12):2179–2187.  https://doi.org/10.1002/jbmr.2565 CrossRefPubMedGoogle Scholar
  14. 14.
    Sambrook PN, Chen JS, Simpson JM, March LM (2010) Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust 193(3):154–156PubMedGoogle Scholar
  15. 15.
    Waller PC, Evans SJ, Beard K (2006) Drug safety and the media. Br J Clin Pharmacol 61(2):123–126.  https://doi.org/10.1111/j.1365-2125.2005.02528.x CrossRefPubMedGoogle Scholar
  16. 16.
    McIntosh J, Blalock SJ (2005) Effects of media coverage of Women’s Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 62(1):69–74PubMedGoogle Scholar
  17. 17.
    Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, da Hanley, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60(4):324–333PubMedPubMedCentralGoogle Scholar
  18. 18.
    McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM (2013) Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126(1):13–20.  https://doi.org/10.1016/j.amjmed.2012.06.023 CrossRefPubMedGoogle Scholar
  19. 19.
    Diab DL, Watts NB (2013) Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 5(3):107–111.  https://doi.org/10.1177/1759720X13477714 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F (2012) Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res 27(5):963–974.  https://doi.org/10.1002/jbmr.1570 CrossRefPubMedGoogle Scholar
  21. 21.
    Compston JE, Bilezikian JP (2012) Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 27(2):240–242.  https://doi.org/10.1002/jbmr.1542 CrossRefPubMedGoogle Scholar
  22. 22.
    Drake MT, Clarke BL, Lewiecki EM (2015) The pathophysiology and treatment of osteoporosis. Clin Ther 37(8):1837–1850.  https://doi.org/10.1016/j.clinthera.2015.06.006 CrossRefPubMedGoogle Scholar
  23. 23.
    Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937.  https://doi.org/10.1002/jbmr.2202 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone 57(2):423–428.  https://doi.org/10.1016/j.bone.2013.09.008 CrossRefPubMedGoogle Scholar
  25. 25.
    Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351 (correction: 2001;2020:2655)CrossRefPubMedGoogle Scholar
  26. 26.
    Joinpoint Regression Program. Version 4.5.01 - June 2017 edn Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer InsitituteGoogle Scholar
  27. 27.
    US Preventive Services Task Force (2011) Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. AnnInternMed 154:356–364Google Scholar
  28. 28.
    Miller PD (2016) Underdiagnosis and undertreatment of osteoporosis: the battle to be won. J Clin Endocrinol Metab 101(3):852–859.  https://doi.org/10.1210/jc.2015-3156 CrossRefPubMedGoogle Scholar
  29. 29.
    Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the U.S. Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 31(8):1536–1540.  https://doi.org/10.1002/jbmr.2832 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Khosla S, Shane E (2016) A crisis in the treatment of osteoporosis. J Bone Miner Res 31(8):1485–1487.  https://doi.org/10.1002/jbmr.2888 CrossRefPubMedGoogle Scholar
  31. 31.
    Imel EA, Eckert G, Modi A, Li Z, Martin J, de Papp A, Allen K, Johnston CC, Hui SL, Liu Z (2016) Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates. Bone 83:267–275.  https://doi.org/10.1016/j.bone.2015.11.021 CrossRefPubMedGoogle Scholar
  32. 32.
    Wright NC, Saag KG, Curtis JR, Smith WK, Kilgore ML, Morrisey MA, Yun H, Zhang J, Delzell ES (2012) Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res 27(11):2325–2332.  https://doi.org/10.1002/jbmr.1684 CrossRefPubMedGoogle Scholar
  33. 33.
    Looker AC, Frenk SM (2015) Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005–2010. Division of Health and Nutrition Examination Surveys, CDCGoogle Scholar
  34. 34.
    US Census Bureau (2016) Population 65 years and over in the United States, 2015 American Community Survey 1-Year Estimates. https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=ACS_15_1YR_S0103&prodType=table Accessed November 13, 2017
  35. 35.
    US Census Bureau (2001) Female population by age, race and Hispanic or Latino origin for the United States: 2000 https://www.census.gov/population/www/cen2000/briefs/phc-t9/tables/tab03.pdf, Accessed November 13, 2017

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Authors and Affiliations

  1. 1.New Mexico Clinical Research & Osteoporosis CenterAlbuquerqueUSA
  2. 2.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Department of Medicine, Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA
  4. 4.Department of MedicineColumbia University Medical CenterNew YorkUSA
  5. 5.Department of Endocrine NeoplasiaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  6. 6.Department of Obstetrics and GynecologyMedStar Georgetown University HospitalWashingtonUSA
  7. 7.Department of MedicineMedStar Georgetown University HospitalWashingtonUSA
  8. 8.International Society for Clinical DensitometryHartfordUSA
  9. 9.Endocrinology SectionMcGuire Veterans Affairs Medical CenterRichmondUSA
  10. 10.Virginia Commonwealth University School of MedicineRichmondUSA

Personalised recommendations